X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Generic Version of Medrol

    Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Version of Medrol

    Fig extract for healthy blood sugar levels

    Fig extract for healthy blood sugar levels

    Novartis ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Generic Version of Medrol

    Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Version of Medrol

    Fig extract for healthy blood sugar levels

    Fig extract for healthy blood sugar levels

    Novartis ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

UCC RESEARCH TO HELP MALARIA VACCINE DEVELOPMENT

Yuvraj_pawp by Yuvraj_pawp
3rd September 2014
in Europe, News, Research & Development
3image

Researchers at UCC have developed a microneedle-based patch that results in increased vaccine-induced protection against malaria infection using lower doses of vaccine in pre-clinical testing. The lead researcher, Dr Anne Moore, heads to Silicon Valley next week to meet venture capitalists and leading technology companies with a view to commercialising the research.

The microneedle-based patch also overcomes one of the main problems with this type of vaccine which relates to overcoming pre-existing immunity to the vaccine. The scientists combined two vaccine technologies to determine if immunity could be further enhanced and the research suggests that using a microneedle patch would overcome the need to make and use multiple different vaccine types to induce protective immunity to some of the world’s biggest killers. This could have significant consequences on the costs and logistics of vaccination.

The work was carried out by researchers in the School of Pharmacy, Dept. of Pharmacology and the Tyndall National Institute, UCC, led by Dr Anne Moore in collaboration with colleagues at the Jenner Institute, University of Oxford and was published by Nature Publication Group in Scientific Reports and funded by Enterprise Ireland and Science Foundation Ireland. Dr Moore’s visit to Silicon Valley is being hosted by the Irish Technology Leadership Group (ITLG) as part of an SFI initiative for researchers to help them develop their entrepreneurial skills in the Get Started Venture Technology programme.

The skin patch has arrays of tiny silicon ‘microneedles’ that painlessly create temporary pores in the very outermost barrier layer of the skin, permitting the vaccine to flow into the skin, which is rich in cells of the immune system. The experimental vaccine was based on a live adenovirus. This virus is similar to those that can cause a common cold, but is engineered to be safer and to deliver a protein from the malaria-causing parasite, to the immune system.

Adenoviruses are one of the most potent vaccine platforms tested to date in humans and they are being developed to prevent or treat diseases such as malaria, HIV, influenza and Ebola and to combat other infectious diseases related to biodefence. An obstacle with this vaccine platform is that, although it is great for inducing high levels of immunity to the malaria or HIV protein of interest, a strong immune response to the adenovirus itself is also induced. This robust anti-adenovirus immunity prevents its repeated use as a vaccine as the immune system recognises the adenovirus and prevents it from delivering the malaria protein, so another vaccine type or adenovirus strain needs to be used in the booster immunization.

“What’s exciting from this work,” says Dr Moore “is that administration of this vaccine with the microneedle patch did not induce this strong anti-adenovirus immunity, even though very potent immunity to the malaria antigen is generated.” The team demonstrated that using the microneedle patch in the primary immunization does indeed permit repeated use of the same adenovirus vaccine and this immunization method induces potent and highly protective immune responses against malaria in pre-clinical studies.

Tags: Europe
Previous Post

InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®

Next Post

ViiV Healthcare’s Triumeq for HIV treatment receives EU marketing authorisation

Related Posts

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
Drug Development

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

26th November 2019
Elsevier and FDA to work on AI algorithm for drug-induced liver injury
Americas

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

26th November 2019
Med-Tech Innovation Expo and Medilink UK renew partnership
Drug Development

Med-Tech Innovation Expo and Medilink UK renew partnership

26th November 2019
Lilly to invest $400m to boost manufacturing capacity in US
Americas

Lilly to invest $400m to boost manufacturing capacity in US

26th November 2019
ConvergeHEALTH by Deloitte Launches New Digital Health Ecosystem Platforms at HLTH Conference
News

ConvergeHEALTH by Deloitte Launches New Digital Health Ecosystem Platforms at HLTH Conference

4th November 2019
Foamix Enters Manufacturing Agreement with ASM Aerosol-Service for Topical Foam Treatment
Manufacturing

Foamix Enters Manufacturing Agreement with ASM Aerosol-Service for Topical Foam Treatment

4th November 2019
Next Post

ViiV Healthcare’s Triumeq for HIV treatment receives EU marketing authorisation

Latest News

CPhI Worldwide pointing 2020 to be a strong year for pharma
Manufacturing

CPhI Worldwide pointing 2020 to be a strong year for pharma

3rd December 2019
Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
Drug Development

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

26th November 2019
Elsevier and FDA to work on AI algorithm for drug-induced liver injury
Americas

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

26th November 2019
Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film
FDA Approvals

Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

26th November 2019
Med-Tech Innovation Expo and Medilink UK renew partnership
Drug Development

Med-Tech Innovation Expo and Medilink UK renew partnership

26th November 2019
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In